A4250 (odevixibat)
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Progressive Familial Intrahepatic Cholestasis
Conditions
Progressive Familial Intrahepatic Cholestasis
Trial Timeline
Sep 28, 2018 → Dec 2, 2025
NCT ID
NCT03659916About A4250 (odevixibat)
A4250 (odevixibat) is a phase 3 stage product being developed by Ipsen for Progressive Familial Intrahepatic Cholestasis. The current trial status is completed. This product is registered under clinical trial identifier NCT03659916. Target conditions include Progressive Familial Intrahepatic Cholestasis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03659916 | Phase 3 | Completed |
Competing Products
20 competing products in Progressive Familial Intrahepatic Cholestasis